Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan–Treated Human Epidermal Growth Factor Receptor 2–Positive Gastric Cancer
JCO Precision Oncology · 2026-05 · 10 (5)
DOI: 10.1200/po-25-00823 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift JCO Precision Oncology, 2026-05. Verfasst von Ansh Kapil und 20 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca Computational Pathology GmbH, Oncology Research and Development, Munich, Germany. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Image Processing, Computer-Assisted, Immunoconjugates, Stomach Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate approved for human epidermal growth factor receptor 2 (HER2)–positive gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA). Eligibility for T-DXd therapy currently relies on conventional HER2 immunohistochemistry (IHC) scoring per ASCO/CAP guidelines. Computational pathology tools such as quantitative continuous scoring (QCS) offer precise quantification of HER2 expression, enabling improved scores reflective of T-DXd's mechanism of action. METHODS We used HER2-QCS scoring to identify biomarker signatures in the DESTINY-Gastric01 cohort, with external validation in DESTINY-Gastric02. RESULTS QCS-derived continuous spatial proximity score (cSPS) and density of HER2-positive cells in tumor epithelium (DPC) displayed significant survival benefits for biomarker-positive versus biomarker-negative patients in the DESTINY-Gastric01 T-DXd arm (Cox regression: P < .0001). These signatures were validated in the DESTINY-Gastric02 cohort (log-rank P < .0001). CONCLUSION Our findings indicate that cSPS and DPC are predictive of T-DXd clinical outcomes, supporting the potential future use of QCS as a quantitative approach to identify patients with GC who might benefit most from T-DXd therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- AstraZeneca Computational Pathology GmbH, Oncology Research and Development, Munich, Germany.
- AstraZeneca Translational Medicine, Early Oncology, Cambridge, UK.
- Daiichi Sankyo Inc, Tokyo, Japan.
- Daiichi Sankyo Inc, Basking Ridge, NJ.
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea.
- AstraZeneca, Waltham, MA.
ORCID-Profile: Ansh Kapil, Henrik Failmezger, Andreas Spitzmüller, Anatoliy Shumilov, Fumitaka Suto, Jeeyun Lee, Günter Schmidt
Zitieren
APA
Kapil, A., Failmezger, H., Fu, Y., Spitzmüller, A., Chan, J., Haneder, S., Shumilov, A., Barkell, A., Oguma, T., Inaki, K., Suto, F., Allard, J., Lee, J., Lambert, A. W., Schick, M., Barrett, J. C., Schmidt, G., Sade, H., Gustavson, M., …, & Cecchi, F. (2026). Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan–Treated Human Epidermal Growth Factor Receptor 2–Positive Gastric Cancer. JCO Precision Oncology, 10(5). https://doi.org/10.1200/po-25-00823
Vancouver
Kapil A, Failmezger H, Fu Y, Spitzmüller A, Chan J, Haneder S, et al. Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan–Treated Human Epidermal Growth Factor Receptor 2–Positive Gastric Cancer. JCO Precision Oncology. 2026;10(5). doi:10.1200/po-25-00823
BibTeX
@article{Kapil2026,
author = {Kapil, Ansh and Failmezger, Henrik and Fu, Yu and Spitzmüller, Andreas and Chan, Jessica and Haneder, Susanne and Shumilov, Anatoliy and Barkell, Alice and Oguma, Toshihiro and Inaki, Koichiro and Suto, Fumitaka and Allard, John and Lee, Jeeyun and Lambert, Arthur W and Schick, Markus and Barrett, J Carl and Schmidt, Günter and Sade, Hadassah and Gustavson, Mark and Carroll, Danielle and Cecchi, Fabiola},
title = {Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan–Treated Human Epidermal Growth Factor Receptor 2–Positive Gastric Cancer},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {5},
doi = {10.1200/po-25-00823}
}
EUVIMED